Companies with global potential need different kinds of pathways to make the impact they deserve, writes Richard Lennox, entrepreneur and scale-up advisor; former Skyscanner director and Current Health COO.
Data scientists and clinical researchers are working with high street opticians for the first time to develop a digital tool that can predict a person’s risk of dementia from a routine eye test.
Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma, Inc.
A new drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by biopharmaceutical company Nuvectis Pharma, Inc., has received US Food and Drug Administration (FDA) clearance to proceed to clinical trials.
What’s your next challenge? Spin in, spin out or start up?
